187 related articles for article (PubMed ID: 28771849)
1. In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.
Lesniak WG; Aboye T; Chatterjee S; Camarero JA; Nimmagadda S
Chemistry; 2017 Oct; 23(58):14469-14475. PubMed ID: 28771849
[TBL] [Abstract][Full Text] [Related]
2. Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo.
Chaudhuri D; Lu T; Jacob B; Abraham S; Shankar P; Poss MA; Neamati N; Camarero JA
J Control Release; 2023 Jul; 359():26-32. PubMed ID: 37236320
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.
Lesniak WG; Sikorska E; Shallal H; Behnam Azad B; Lisok A; Pullambhatla M; Pomper MG; Nimmagadda S
Mol Pharm; 2015 Mar; 12(3):941-53. PubMed ID: 25590535
[TBL] [Abstract][Full Text] [Related]
4. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.
De Silva RA; Peyre K; Pullambhatla M; Fox JJ; Pomper MG; Nimmagadda S
J Nucl Med; 2011 Jun; 52(6):986-93. PubMed ID: 21622896
[TBL] [Abstract][Full Text] [Related]
5. Rapid parallel synthesis of bioactive folded cyclotides by using a tea-bag approach.
Aboye T; Kuang Y; Neamati N; Camarero JA
Chembiochem; 2015 Mar; 16(5):827-33. PubMed ID: 25663016
[TBL] [Abstract][Full Text] [Related]
6. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity.
Aboye TL; Ha H; Majumder S; Christ F; Debyser Z; Shekhtman A; Neamati N; Camarero JA
J Med Chem; 2012 Dec; 55(23):10729-34. PubMed ID: 23151033
[TBL] [Abstract][Full Text] [Related]
7. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4).
Woodard LE; De Silva RA; Behnam Azad B; Lisok A; Pullambhatla M; G Lesniak W; Mease RC; Pomper MG; Nimmagadda S
Nucl Med Biol; 2014 Aug; 41(7):552-61. PubMed ID: 25038987
[TBL] [Abstract][Full Text] [Related]
8.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
10. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
11. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.
Nimmagadda S; Pullambhatla M; Pomper MG
J Nucl Med; 2009 Jul; 50(7):1124-30. PubMed ID: 19525448
[TBL] [Abstract][Full Text] [Related]
12. Second generation Al
Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
[TBL] [Abstract][Full Text] [Related]
13. Development and Evaluation of an
Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO
Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140
[TBL] [Abstract][Full Text] [Related]
14. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
[TBL] [Abstract][Full Text] [Related]
15. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts.
Azad BB; Chatterjee S; Lesniak WG; Lisok A; Pullambhatla M; Bhujwalla ZM; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(11):12344-58. PubMed ID: 26848769
[TBL] [Abstract][Full Text] [Related]
16. Cyclotides, a versatile ultrastable micro-protein scaffold for biotechnological applications.
Camarero JA
Bioorg Med Chem Lett; 2017 Dec; 27(23):5089-5099. PubMed ID: 29110985
[TBL] [Abstract][Full Text] [Related]
17. [
Amor-Coarasa A; Kelly J; Ponnala S; Vedvyas Y; Nikolopoulou A; Williams C; Jin MM; David Warren J; Babich JW
Nucl Med Biol; 2018 May; 60():37-44. PubMed ID: 29544122
[TBL] [Abstract][Full Text] [Related]
18. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel
Zhang X; You L; Chen S; Gao M; Guo Z; Du J; Lu J; Zhang X
J Labelled Comp Radiopharm; 2018 May; 61(5):438-446. PubMed ID: 29370457
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas.
Demoin DW; Shindo M; Zhang H; Edwards KJ; Serganova I; Pillarsetty NV; Lewis JS; Blasberg RG
Nucl Med Biol; 2016 Oct; 43(10):606-11. PubMed ID: 27485481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
